Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.72)
# 1,861
Out of 5,150 analysts
103
Total ratings
32.73%
Success rate
0.43%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $6.07 | +64.74% | 5 | Mar 2, 2026 | |
| MNKD MannKind | Maintains: Buy | $11 → $8 | $2.95 | +171.19% | 9 | Feb 27, 2026 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $4.24 | +206.60% | 5 | Feb 11, 2026 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $1.03 | +778.05% | 3 | Feb 10, 2026 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $20 | $15.45 | +29.45% | 3 | Feb 10, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $5.76 | +403.47% | 2 | Feb 3, 2026 | |
| CRMD CorMedix | Maintains: Buy | $18 → $13 | $7.12 | +82.58% | 5 | Jan 23, 2026 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $6 | $1.13 | +430.97% | 3 | Jan 9, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $46 → $60 | $39.61 | +51.48% | 8 | Jan 9, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $12.91 | +62.73% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $1.36 | +708.82% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $8.19 | +46.52% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $11.59 | +245.13% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.65 | +384.85% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $23.00 | +160.87% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.70 | +370.59% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.19 | +740.34% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $76.53 | +58.11% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $10.97 | +64.08% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.07 | +61.19% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.58 | +162.01% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.64 | +165.15% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.95 | +190.50% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.89 | +458.72% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.99 | +9,950.25% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.81 | +81.71% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $8.71 | +5,123.88% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $20.11 | +193.46% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $188.69 | -4.61% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.51 | +8,664.94% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.25 | +9.40% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $0.94 | +2,340,325.53% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $10.62 | +371.03% | 1 | Jul 12, 2018 |
Xeris Biopharma Holdings
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $6.07
Upside: +64.74%
MannKind
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $2.95
Upside: +171.19%
PolyPid
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.24
Upside: +206.60%
Cardiol Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.03
Upside: +778.05%
Enanta Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $15.45
Upside: +29.45%
Sagimet Biosciences
Feb 3, 2026
Reiterates: Buy
Price Target: $29
Current: $5.76
Upside: +403.47%
CorMedix
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.12
Upside: +82.58%
Heron Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.13
Upside: +430.97%
Collegium Pharmaceutical
Jan 9, 2026
Reiterates: Buy
Price Target: $46 → $60
Current: $39.61
Upside: +51.48%
Trevi Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $21
Current: $12.91
Upside: +62.73%
Jan 9, 2026
Reiterates: Buy
Price Target: $11
Current: $1.36
Upside: +708.82%
Jan 9, 2026
Reiterates: Buy
Price Target: $12
Current: $8.19
Upside: +46.52%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $11.59
Upside: +245.13%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.65
Upside: +384.85%
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $23.00
Upside: +160.87%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.19
Upside: +740.34%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $76.53
Upside: +58.11%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $10.97
Upside: +64.08%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $8.07
Upside: +61.19%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.58
Upside: +162.01%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.64
Upside: +165.15%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.95
Upside: +190.50%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.89
Upside: +458.72%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.99
Upside: +9,950.25%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.81
Upside: +81.71%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $8.71
Upside: +5,123.88%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $20.11
Upside: +193.46%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $188.69
Upside: -4.61%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.51
Upside: +8,664.94%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.25
Upside: +9.40%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $0.94
Upside: +2,340,325.53%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $10.62
Upside: +371.03%